Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2005-09-13
2005-09-13
Zucker, Paul A. (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S563000, C560S046000
Reexamination Certificate
active
06943191
ABSTRACT:
Disubstituted lavendustin A analogs that are PTK inhibitors having antiproliferative activity are described. Preferred compounds of the disclosure, without limitation, satisfy either Formula 1 or Formula 2.The present disclosure also provides pharmaceutical compositions comprising effective amounts of disubstituted lavendustin A analogs and potentially comprising other active ingredients, other materials conventionally used in the formulation of pharmaceutical compositions, and mixtures thereof. The compounds and compositions of the disclosure can be used for treating subjects to, for example, inhibit the proliferation of living cells in the treatment of proliferative diseases.
REFERENCES:
patent: 4828568 (1989-05-01), Konrad et al.
patent: 4833164 (1989-05-01), Batt
patent: 4853403 (1989-08-01), Shiraishi et al.
patent: 4971996 (1990-11-01), Shiraishi et al.
patent: 5122537 (1992-06-01), Buzzetti et al.
patent: 5124354 (1992-06-01), Green
patent: 5216023 (1993-06-01), Literati et al.
patent: 5326905 (1994-07-01), Dow et al.
patent: 5328914 (1994-07-01), Hocquaux et al.
patent: 5374652 (1994-12-01), Buzzetti et al.
patent: 5409949 (1995-04-01), Buzzetti et al.
patent: 5436235 (1995-07-01), Buzzetti et al.
patent: 5446168 (1995-08-01), Ditrich et al.
patent: 5457105 (1995-10-01), Barker
patent: 5457237 (1995-10-01), Dow
patent: 5488057 (1996-01-01), Buzzetti et al.
patent: 5491147 (1996-02-01), Boyd et al.
patent: 5506211 (1996-04-01), Barnes et al.
patent: 5514711 (1996-05-01), Kitano et al.
patent: 5519018 (1996-05-01), Matusch et al.
patent: 5554519 (1996-09-01), Weber et al.
patent: 5580888 (1996-12-01), Warrellow et al.
patent: 5587385 (1996-12-01), Buzzetti et al.
patent: 5587459 (1996-12-01), Uckun
patent: 5593997 (1997-01-01), Dow et al.
patent: 5608070 (1997-03-01), Alexander et al.
patent: 5610185 (1997-03-01), Stanwell et al.
patent: 5616582 (1997-04-01), Barker
patent: 5618829 (1997-04-01), Takayanagi et al.
patent: 5622977 (1997-04-01), Warrellow et al.
patent: 5627207 (1997-05-01), Buzzetti et al.
patent: 5633257 (1997-05-01), Warrellow et al.
patent: 5639757 (1997-06-01), Dow et al.
patent: 5648378 (1997-07-01), Huang
patent: 5650415 (1997-07-01), Tang et al.
patent: 5652250 (1997-07-01), Buzzetti et al.
patent: 5656654 (1997-08-01), Buzzetti et al.
patent: 5661126 (1997-08-01), Donahoe et al.
patent: 5663346 (1997-09-01), Buzzetti et al.
patent: 5674880 (1997-10-01), Boyd et al.
patent: 5677320 (1997-10-01), Chandraratna
patent: 5677323 (1997-10-01), Chandraratna
patent: 853482 (1960-11-01), None
patent: WO 93 23364 (1993-01-01), None
patent: WO 93 23364 (1993-11-01), None
patent: WO 94 26260 (1994-01-01), None
patent: WO 94 26260 (1994-11-01), None
patent: WO 95 21613 (1995-08-01), None
patent: WO 96 40115 (1996-02-01), None
Liu et al., “Synthesis and Biological Activity of 5-′(2,5-dihydroxybenzyl)amino!salicylic Acid Analogs as Inhibitors of EGF Receptor-Associated Protein Tyrosine Kinase,” BioOrg. Med. Chem. Lett. (1997), 7(3), 365-368.
Chen et al., “Structure-Activity Relationships in a Series of 5-′(2,5-dihydroxybenzyl)amino!salicylate Inhibitors of EGF-Receptor-Associated Tyrosine Kinase: Importance of Additional Hydrophobic Aromatic Interactions,” J. Med. Chem. (1994), 37(6), 845-59.
Chen et al., “Synthesis and Structure-Activity Studies of a Series of ′(hydrozybenzyl)amino!salicylates as Inhibitors of EGF Receptor-Associated Tyrosine Kinase Activity,” J. Med. Chem. (1993), 36(25), 4094-8.
Chen et al., “Synthesis and Biological Evaluation of Series of Hydroxybenzylphenylamine Derivatives as Inhibitors of EGF Receptor-Associated Tyrosine Kinase Activity,” Anti-Cancer Drug Des. (1996), 11(1), 49-71.
Nussbaumer et al., “Novel Antiproliferative Agents Derived from Lavendustin A,” J. Med. Chem. (1994), 37(24), 4979-84.
Smyth et al., “Non-Amine Based Analogues of Lavendustin A as Protein-Tyrosine Kinase Inhibitors,”J. Med. Chem.,36, 3010-14 (1993).
Gazit et.al., “Tyrophostins. 2. Heterocyclic and60-Substituted Benzylidenemalononitrile Tyrphostins as Potent Inhibitors of EGF Receptor and Erb2
eu Tyrosine Kinases,”J. Med. Chem.,34, 1896-1907 (1991).
Traxler et al., “Sulfonylbenzoyl-Nitrostyrenes: Potential Bisubstrate Type Inhibitors of the EGF-Receptor Tyrosine Protein Kinase,”J. Med. Chem.,34, 2328-37 (1991).
Kaur and Sausville, “Altered Physical States of p210bcr-ablin Tyrphostin AG957-Treated K562 Cells,”Anti-Cancer Drugs, 7, 815-24 (1996).
Smyth et al., “Hydroxylated 2-(5'-Salicyl)naphthalenes as Protein-Tyrosine Kinase Inhibitors,”J. Med. Chem.,36, 3015-20 (1993).
Burke, Jr., “Protein-Tyrosine Kinases: Potential Targets for Anticancer Drug Development,”Stem Cells,12, 1-6 (1994).
Gazit et al., “Tyrphostins I: Synthesis and Biological Activity of Protein Tyrosine Kinase Inhibitors,”J. Med. Chem.,32, 2344-52 (1989).
Liu et al., “Synthesis and Biological Activity of 5-′(2,5-dihydroxybenzyl)aminosalicylic Acid Analogs as Inhibitors of EGF Receptor-Associated Protein Tyrosine Kinase,”BioOrg. Med. Chem. Lett.,7(3), 365-68 (1997).
Chen et al., “Structure-Activity Relationships in a Series of 5-′(2,5-dihydroxybenzyl)aminosalicylate Inhibitors of EGF-Receptor-Associated Tyrosine Kinase: Importance of Additional Hydrophobic Aromatic Interactions,”J. Med. Chem.,37, 845-59 (1994).
Chen et al., “Synthesis and Structure-Activity Studies of a Series of [(Hydroxybenzyl)amino]salicylates as Inhibitors of EGF Receptor-Associated Tyrosine Kinase Activity,” J. Med. Chem., 36, 4094-8 (1993).
Chen et al., “Synthesis and Biological Evaluation of Series of Hydroxybenzylphenylamine Derivatives as Inhibitors of EGF Receptor-Associated Tyrosine Kinase Activity,”Anti-Cancer Drug Des.,11, 49-71 (1996).
Nussbaumer et al., “Novel Antiproliferative Agents Derived from Lavendustin A,”J. Med. Chem.,37, 4979-84 (1994).
Kaur Gurmeet
Narayanan Venkatachala L.
Sausville Edward A.
Varma Ravi K.
Klarquist & Sparkman, LLP
The United States of America as represented by the Department of
Zucker Paul A.
LandOfFree
Disubstituted lavendustin A analogs and pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Disubstituted lavendustin A analogs and pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Disubstituted lavendustin A analogs and pharmaceutical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3437978